Who We Are
Nexaph Reviews is an independent editorial project covering public discussion and community sentiment around the Nexaph peptide vendor name. We are not Nexaph, not a reseller, not a competitor, and not an affiliate of any vendor. The site exists because most pages answering “is this vendor legit” are marketing in disguise - affiliate funnels, astroturfed reviews, or scraped filler - and readers deserve a source whose incentives are visible.
Our editorial team has professional backgrounds in life-science research and science writing. We hold no financial interest, direct or indirect, in any peptide vendor.
Nexaph Reviews Our Methodology
Everything on this site derives from two source classes, handled differently:
- Published science. Peer-reviewed literature and clinical trial publications are cited as such - for example, the retatrutide Phase 2 results reported in the New England Journal of Medicine (2023). Where we summarize trial findings, we describe what the trial reported, not what any product will do.
- Public community discussion. Reddit threads, forum posts, Telegram channels and review platforms are summarized as community reports - patterns of what people say, never presented as verified fact. Where a claim is unverifiable, we say so.
We do not conduct covert purchases, we do not run lab tests, and we do not accept leaked documents. Our value is aggregation, framing and literacy - not investigation.
Editorial Standards
- Independence: no vendor payments, referral fees, free products or reciprocal promotion, ever.
- Labeling: anecdote, community consensus, and published evidence are visually and textually distinguished.
- No verdicts: we do not score or certify grey-market vendors, in either direction.
- No medical advice: nothing on this site is medical advice, and we do not encourage obtaining prescription compounds outside licensed channels.
- Corrections: material errors are corrected promptly and noted. See Contact & Corrections.
Evidence Hierarchy: How Claims Are Sorted
Before anything is written, every available claim about the vendor or the compounds is assigned to a tier, and the tier determines how the claim may be used. This is the operating system of the entire site:
| Evidence tier | Example | Reliability | How we use it |
|---|---|---|---|
| Peer-reviewed clinical trials | NEJM, Lancet publications | Highest | Cited directly, with trial name and sample size |
| Regulator publications | FDA, MHRA, EMA statements and approvals | High | Cited directly |
| Named third-party lab reports | Independent analytical lab COAs | Medium (verifiable only with the lab) | We report their existence, not their conclusions as fact |
| Public community discussion | Reddit threads, Telegram posts | Low - anecdote | Summarized as patterns, always labeled |
| Anonymous testimonials | Review-site posts | Lowest | Counted, never endorsed or repeated as fact |
Two rules make the hierarchy strict rather than decorative. First, tier discipline is one-way: a tier-4 claim (community report) can never be promoted to a higher tier by repetition, popularity, or volume - a thousand anecdotes remain anecdote. Second, tier-3 documents are reported, not adopted: when a third-party lab report exists, we say that it exists and what it states, but a vendor-side or even community-submitted document cannot be treated as regulator-grade verification unless the lab itself confirms it. These rules are why our pages read differently from typical “review” sites, which silently mix all five tiers into single verdict sentences.
Nexaph Reviews The Source Register
Concretely, the sources that feed coverage on this site, and their handling rules:
| Source type | Examples used on this site | Handling rule |
|---|---|---|
| Peer-reviewed literature | STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), retatrutide Phase 2 (NEJM 2023) | Cited with trial name, sample size and duration; summarized, never extrapolated |
| Regulator publications | FDA shortage determinations and warning letters; MHRA #FakeMeds warnings; NICE guidance | Cited as public record |
| Public survey and market research | KFF Health Tracking Poll (May 2024); Goldman Sachs Research projections (2023) | Cited with pollster and date; projections labeled as projections |
| Published price references | U.S. list prices for approved GLP-1s (2024, pre-discount); commonly reported UK private prescription ranges | Presented as reference parameters, not quotes; dated explicitly |
| Community discussion | Reddit threads, Telegram channels, review platforms | Summarized as labeled anecdote; never presented as fact |
What is deliberately absent from the register: covert purchases, lab tests commissioned by us, leaked documents, and any vendor-supplied material. Each would create either a legal exposure or an undisclosed dependency we do not want. Aggregation, framing and literacy are the product; investigation is not.
The Vendor Evaluation Rubric
Where our coverage does evaluate - vendors in general, never a specific verdict for one - it applies a weighted rubric, published in full on the legitimacy page:
| Parameter | Weight | Rationale |
|---|---|---|
| Batch-specific COAs | 25% | The only vendor-side artifact that speaks to vial contents |
| Named third-party testing | 25% | The only outward-pointing quality signal in the market |
| Multi-year track record | 20% | Consistency over time is expensive to fake |
| Domain & business transparency | 10% | Durability proxy |
| Payment recourse | 10% | Risk allocation reveals seller confidence |
| Review ecology | 10% | Manipulation detection layer |
Note the design: half the weight goes to the two parameters that address what is in the vial, because that is the question that matters most and the one testimonials cannot answer. We publish the rubric but publish no scores - a score computed from anonymous sentiment would be false precision, which violates the evidence hierarchy above.
Limitations, Stated Plainly
This methodology has hard limits and readers should know them. We cannot verify any vendor’s products, ever - only regulators and named labs can approach that. Community sentiment is manipulable, so our summaries of it carry inherent uncertainty that no framing fully removes. Published trial data describes supervised clinical use, which is precisely not the use case most of our readers are evaluating. And pricing references date quickly in a fast-moving market. Where any of these limits touch a specific page, the page says so; where coverage becomes outdated, the corrections channel is open and substantive corrections are made promptly and noted.
Trademark Statement
Independent Site Notice: This is an independent, unaffiliated review website. We are NOT affiliated, endorsed, sponsored, or connected in any way with Nexaph. All trademarks belong to their respective owners. This site only provides user-submitted public information and third-party reviews for educational reference.
Our use of the Nexaph name is nominative fair use: identifying the subject of public discussion and consumer research, which is the name the public uses to search for it. We do not use vendor logos, product imagery or brand assets, and nothing here suggests endorsement, affiliation or authorization.
Advertising Disclosure
This site displays clearly-labeled advertising in reserved ad slots, served identically to all visitors. Advertising never influences editorial content, and no vendor can pay for coverage, placement within coverage, or removal of coverage. Full details on the Disclaimers page.